{"id":"NCT00493870","sponsor":"US Oncology Research","briefTitle":"TAC Versus TC for Adjuvant Breast Cancer","officialTitle":"Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05-29","primaryCompletion":"2015-05-31","completion":"2020-03-30","firstPosted":"2007-06-28","resultsPosted":"2023-03-02","lastUpdate":"2023-03-02"},"enrollment":1961,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Docetaxel","otherNames":["Taxotere"]},{"type":"DRUG","name":"Doxorubicin","otherNames":["Adriamycin"]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":["Cytoxan"]}],"arms":[{"label":"TC","type":"EXPERIMENTAL"},{"label":"TAC","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.","primaryOutcome":{"measure":"3-year Invasive Disease-free Survival (IDFS) Among Analyzed ITT Patients","timeFrame":"3 years from randomization into study","effectByArm":[{"arm":"TC Arm","deltaMin":91.1,"sd":null},{"arm":"TAC Arm","deltaMin":93.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.05"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":95,"countries":["United States"]},"refs":{"pmids":["38335467"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":264,"n":969},"commonTop":["ALOPECIA","FATIGUE","NAUSEA","DIARRHEA","NEUTROPENIA"]}}